Epidemiological and overall survival characteristics of thyroid cancers in Ege University hospital database
Abstract
Aim: To evaluate epidemiologic features and survival outcomes of 8450 patients treated with the diagnosis of thyroid cancer in Ege University Hospital (EUH) between 1992-2017 and compare them with the literature.
Materials and Methods: The thyroid cancer patients’ data that was collected by Ege University Cancer Research Center, was recorded to CANREG computer program, and analyses was performed according to WHO and SEER system definitions. Chi-square, General Linear Model and Kaplan-Meier survival analyses was performed for further analyses. Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon) and Tarone-Ware statistics was used for survival analyses. P<0,05 was considered as statistically significant.
Results: A total of 8450 patients diagnosed with thyroid cancer in 1763 male (20.9%), 6687 female (79.1%) between 1992 and 2017 were evaluated in Ege University Hospital. Looking at the age group of thyroid cancers, it was seen that the median age was 40-49 (26.2%). When the histological types of thyroid cancer were examined, it was found that 91.2% of the patients were diagnosed with PTC, 5.7% of the patients with FTC, 2.3% of them with MTC and 0.7% of them with ATC. When the PTC subtypes, which is the most common thyroid cancer type, were examined, classic variant in 3273 cases (43.5%), follicular variant in 1914 cases (25.4%), papillary microcarcinoma in 1819 cases (24.2%), 439 cases ( oncocytic variant (5.8%) and tall cell variant in 21 cases (0.3%) were detected. Male gender, histological type of thyroid cancer and histological variants for papillary cancer were determined as important factors in prognosis (p <0.001).
Conclusion: The worldwide increase in the incidence of thyroid cancer can also be seen in our data. This is especially true for papillary thyroid cancer. Histological type of thyroid cancer and variants of papillary thyroid cancer are the most important factors in survival.
References
- J.P. Brito, L. Davies. Is there really an increased incidence of thyroid cancer? Curr Opin Endocrinol Diabetes Obes. 2014;21(5):405-8.
- Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer. 1997; 79: 564–573.
- Türkiye Kanser Kontrol Programı, T.C.Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu Kanser Daire Başkanlığı, 1. Baskı, sayfa 20-24, Ankara, 2016
- Haydaroğlu A, Sert F, Caner A. Ege Üniversitesi Hastanesi veri tabanındaki kanser olgularının epidemiyolojik ve genel sağ kalım özellikler. Ege Tıp Dergisi 2019;58;1-9.
- Yildirim Simsir I, Cetinkalp S, Kabalak T. Review of Factors Contributing to Nodular Goitre and Thyroid Carcinoma. Med Princ Pract 2020;29:1–5.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL., Torre LA and Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018; 68:394-424.
- T.C. Sağlık Bakanlığı Kanser Araştırma Derneği’nin 2010 yılı raporu, https://hsgm.saglik.gov.tr/tr/kanser-istatistikleri/yillar/2010-yili-kanser-istatistikleri.html
- Gültekın M,Boztaş G; Türkıye Kanser İstatıstıklerı. T.C.Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu, Kanser Savaş Daire Başkanlığı. 2016.
- Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol.2010; 6(11):1771-9.
- Tallini G, Tuttle RM, Ghossein RA. The History of the Follicular Variant of Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2017;102(1):15-22.
- Yu XM, Schneider DF, Leverson G, Chen H, Sippel RS. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases. Thyroid. 2013;23(10):1263-8.
- Tan RK, Finley RK 3rd, Driscoll D, et al. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 1995;17(1):41-7.
- McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001; 130(6):1028-34.
- Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25(6):567-610.
- Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000; 88 (5):1139-48.
- Johnson TL, Lloyd RV, Thompson NW, et al. Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol 1988;12(1):22-7.
- Ghossein R, Livolsi VA. Papillary thyroid carcinoma tall cell variant. Thyroid 2008; 18(11):1179-81.
Abstract
Amaç: Ege Üniversitesi Hastanesinde 1992-2017 yılları arasında tanı alan ve tedavisi yapılan 8.450 tiroit kanserli olgunun epidemiyolojik ve sağ kalım özelliklerini analiz etmek ve sonuçlarını literatürle karşılaştırmak amaçlanmıştır.
Gereç ve Yöntem: Ege Üniversitesi Kanserle Savaş Araştırma ve Uygulama Merkezi tarafından toplanan tiroit kanseri verileri CANREG özel bilgisayar programına kayıt edilmiş, DSÖ ve SEER sistemleri temelinde gruplanarak analizler yapılmıştır. İstatistik analizlerde Ki-kare, General Linear Model, Kaplan Meier sağ kalım analizleri uygulanmıştır. Kaplan Meier sağ kalım analizinde Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon) ve Tarone-Ware istatistikleri kullanılmıştır. İstatistik analizlerde p <0,05 istatistiksel olarak anlamlı kabul edilmiştir.
Bulgular: Ege Üniversitesi Hastanesi’nde 1992-2017 yılları arasında 1.763 erkek (%20,9), 6.687 kadın (%79,1) toplam 8450 tiroit kanseri tanılı olgu değerlendirildi. Tiroit kanserleri medyan yaşı 40-49 (%26,2) olduğu görüldü. Tiroit kanseri histolojik tiplerine bakıldığında hastaların %91,2’sinin PTK (papiller tiroit kanseri), %5,7’sinin FTK (foliküler tiroid kanseri), %2,3’ünün MTK (medüller tiroid kanseri), %0,7’sinin ise ATK (anaplastik tiroid kanseri) tanısı aldığı saptandı. En sık görülen tiroit kanser tipi olan PTK alt tipleri incelendiğinde 3.273 olguda (%43,5) klasik varyant, 1.914 olguda (%25,4) foliküler varyant, 1819 olguda (%24,2) mikrokarsinom, 439 olguda (%5,8) onkositik varyant ve 21 olguda (%0,3) tall cell varyant saptandı. Erkek cinsiyet, hem tiroit kanseri histolojik tipi hem de papiller kanser histolojik varyantları için en önemli prognostik faktör olarak belirlendi (p<0,001).
Sonuç: Tiroit kanseri insidansında tüm dünyada görülen artış verilerimizde de görülebilmektedir. Bu durum özellikle papiller tiroit kanseri için geçerlidir. Tiroit kanserinin histolojik tipi ve ayrıca papiller tiroit kanserinin varyantları sağ kalımda en önemli etmenlerdir.
References
- J.P. Brito, L. Davies. Is there really an increased incidence of thyroid cancer? Curr Opin Endocrinol Diabetes Obes. 2014;21(5):405-8.
- Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer. 1997; 79: 564–573.
- Türkiye Kanser Kontrol Programı, T.C.Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu Kanser Daire Başkanlığı, 1. Baskı, sayfa 20-24, Ankara, 2016
- Haydaroğlu A, Sert F, Caner A. Ege Üniversitesi Hastanesi veri tabanındaki kanser olgularının epidemiyolojik ve genel sağ kalım özellikler. Ege Tıp Dergisi 2019;58;1-9.
- Yildirim Simsir I, Cetinkalp S, Kabalak T. Review of Factors Contributing to Nodular Goitre and Thyroid Carcinoma. Med Princ Pract 2020;29:1–5.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL., Torre LA and Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018; 68:394-424.
- T.C. Sağlık Bakanlığı Kanser Araştırma Derneği’nin 2010 yılı raporu, https://hsgm.saglik.gov.tr/tr/kanser-istatistikleri/yillar/2010-yili-kanser-istatistikleri.html
- Gültekın M,Boztaş G; Türkıye Kanser İstatıstıklerı. T.C.Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu, Kanser Savaş Daire Başkanlığı. 2016.
- Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol.2010; 6(11):1771-9.
- Tallini G, Tuttle RM, Ghossein RA. The History of the Follicular Variant of Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2017;102(1):15-22.
- Yu XM, Schneider DF, Leverson G, Chen H, Sippel RS. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases. Thyroid. 2013;23(10):1263-8.
- Tan RK, Finley RK 3rd, Driscoll D, et al. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 1995;17(1):41-7.
- McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001; 130(6):1028-34.
- Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25(6):567-610.
- Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000; 88 (5):1139-48.
- Johnson TL, Lloyd RV, Thompson NW, et al. Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol 1988;12(1):22-7.
- Ghossein R, Livolsi VA. Papillary thyroid carcinoma tall cell variant. Thyroid 2008; 18(11):1179-81.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Research Articles |
| Authors | |
| Publication Date | October 26, 2020 |
| Submission Date | August 28, 2020 |
| Published in Issue | Year 2020 |